“An experimental hookworm vaccine sharply reduced infection intensity in a Phase 2 trial, with vaccinated participants showing a median of zero detectable worm eggs in their feces after exposure. If approved, this would be the first vaccine for the parasitic disease, which infects hundreds of millions of people each year and is a leading cause of anemia,” reports The Doomslayer.
“Hookworms are small, parasitic roundworms that live in the small intestines of humans and animals, causing infection by feeding on blood and tissues. They are transmitted when larvae in contaminated soil penetrate the skin, usually through bare feet, eventually reaching the intestine. Common symptoms include itchy rash, abdominal pain, diarrhea, and anemia.”
“Worldwide, an estimated 400 to 740 million people are infected with hookworms, primarily in tropical and subtropical regions with poor sanitation,” notes the Cleveland Clinic.
A century ago, hookworm “caused rampant anemia and lethargy in the American South.” Starting in 1909, John D. Rockefeller funded a “pioneering effort to treat and eliminate hookworm across the South. The campaign, which used traveling dispensaries and sanitation education, is credited with establishing modern public health systems.”
Newswise reports:
Researchers at the George Washington University School of Medicine and Health Sciences in partnership with Baylor College of Medicine report encouraging results from a phase 2 clinical trial evaluating a candidate vaccine to prevent hookworm infection – one of the world’s most common parasitic diseases.
The findings, published in The Lancet Infectious Diseases, show that a formulation of the investigational vaccine significantly reduced the intensity of infection in healthy adult volunteers exposed to the parasite under carefully controlled conditions…
- Participants who received the Na-GST 1/Al–CpG vaccine showed a dramatically lower intensity of infection after exposure: maximal hookworm egg count was median 0.0 eggs per gram of feces compared with the placebo group (median 66.7 eggs)
- Peak eosinophil levels – a blood marker linked to parasitic infection – were significantly lower in the Na-GST-1/Al–CpG group of participants.
- This group of participants also produced the highest levels of anti–Na-GST-1 antibodies, suggesting these antibodies may help protect against infection.
